Vistin Pharma ASALTS:0RAM 77 Equity-to-Asset is 0.77 as of Mar. 2026, which is 4% above its 10-year median of 0.74. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.69 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 75.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vistin Pharma ASA's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr350.3 Mil. Vistin Pharma ASA's Total Assets for the quarter that ended in Mar. 2026 was kr453.6 Mil.
Therefore, Vistin Pharma ASA's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.77.
The historical rank and industry rank for Vistin Pharma ASA's Equity-to-Asset or its related term are showing as below:
LTS:0RAM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52 Med: 0.74 Max: 0.87
Current: 0.77
During the past 13 years, the highest Equity to Asset Ratio of Vistin Pharma ASA was 0.87. The lowest was 0.52. And the median was 0.74.
LTS:0RAM's Equity-to-Asset is ranked better than 75.6% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs LTS:0RAM: 0.77
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vistin Pharma ASA Equity-to-Asset Related Terms
Vistin Pharma ASA Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vistin Pharma ASA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Equity-to-Asset of 0.77 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vistin Pharma ASA and its competitors. This is near median its historical median of 0.74. Over the past decade, Vistin Pharma ASA's Equity-to-Asset has ranged from 0.52 to 0.87. According to the industry distribution chart, Vistin Pharma ASA ranks #246 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Vistin Pharma ASA's Equity-to-Asset too high?
Vistin Pharma ASA's current Equity-to-Asset of 0.77 is near median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 0.87. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Vistin Pharma ASA's value of 0.77 is 26.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #246 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #246 out of 1008 companies for Equity-to-Asset. This places Vistin Pharma ASA in the top 24% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Vistin Pharma ASA's value of 0.77 is 26.2% above this benchmark. Historically, Vistin Pharma ASA's own Equity-to-Asset has ranged from 0.52 to 0.87 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 0.61, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Equity-to-Asset of 0.77 is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Equity-to-Asset is 0.77, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.69, compared to a current price of kr20.30 — trading 21% below its estimated fair value. The current Equity-to-Asset is 0.77, which is near median its 10-year median of 0.74 and 26.2% above the Drug Manufacturers industry median of 0.61. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Equity-to-Asset is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.30 is trading 21% below its estimated GF Value™ of kr25.69.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Equity-to-Asset: 0.77 (near median its 10-year median of 0.74)
GF Value™: kr25.69 vs. price of kr20.30 (21% below fair value)
Industry Position: 26.2% above the Drug Manufacturers median (#246 of 1008)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
